Granules India Ltd Q1 FY26 Earnings Analysis

- Oncology portfolio expected to start yielding revenues from FY '28 onwards, with a broad pipeline including first-to-launch and Para IV products. - Expansion of the Europe and Rest of World (ROW) business, focusing on finished dosages and increasing API and PFI business. - Increased focus on formulation segment, aiming for around 25% of revenues from API with emphasis on in-house consumption. - Genome Valley formulation site to play a significant role in revenue growth, especially as Gagillapur facility normalizes post-remediation. - Strategic shift towards high-margin finished dosage products leading to improved gross margins. - Granules Life Sciences capacity utilization projected to increase from about 40% in current year to over 90% next year, driving revenue growth. - Planned continuous R&D and new product launches to sustain medium to long-term growth. - CAPEX to support expansion in GLS and oncology/peptide facilities for future growth. - Slowdown at Gagillapur expected for 1-2 quarters but full-year revenue to improve over last year.

- Oncology portfolio expected to start generating revenue from FY '28 onwards, with multiple filings planned quarterly. - Granules Life Sciences (GLS) expansion to achieve ~40% capacity utilization in FY '25 and close to 90%+ by FY '26 end. - Focus on vertical integration, especially in API, to drive differentiation and margin improvement. - GLS and peptide facilities are priority CAPEX areas, with ₹600 crores planned for FY '26 including Senn Chemicals investment. - Transition toward higher-margin formulations and global markets like Europe and ROW to diversify revenue beyond North America. - Despite ongoing Gagillapur remediation slowing operations, overall improvement over last year is expected. - EBITDA grew 10% in FY '25 and is expected to improve further with better product mix and operational efficiencies. - R&D investment continues to support new product development and differentiated portfolios.

- Granules India spent Rs. 313 crores on Granules Life Sciences (GLS) in FY '25, with additional CAPEX planned in FY '26. - CAPEX for FY '26 is guided at Rs. 600 crores, covering GLS expansion, oncology, and peptide investments. - CZRO project CAPEX is minimal in FY '25, focusing on land acquisition and pilot facilities; expansion to proceed cautiously. - Peptide R&D facility is being set up in Hyderabad, followed by peptide manufacturing. - Senn Chemicals acquisition involves ongoing CAPEX for enhancing CDMO capabilities and GLP-1 product development; the investment is over and above the Rs. 600 crore CAPEX for Granules. - Total CAPEX including Senn Chemicals is expected to be around Rs. 1,100 crores (Rs. 600 crores + Rs. 450 crores enterprise value for Senn). - GLS Phase-II commercial dispatches started; full 7.5 billion dosage capacity commercialization expected by Q2 FY '26. - Peptide and oncology facilities are strategic priorities for future growth.

- The transcript does not explicitly mention any current or planned future fundraising through debt or equity. - Mukesh Surana mentioned CAPEX guidance of Rs. 600 crores for FY '26, which includes investments in Granules Life Science, oncology, peptides, and the Senn Chemicals acquisition. - The Senn Chemicals acquisition involved an enterprise value of Rs. 450 crores, financed through a combination of equity and debt. - There is no direct indication of new fundraising; rather, investments appear to be funded through existing resources, including prior raised capital. - The company is focusing on expansion and CAPEX but has not provided updates on fresh debt or equity raising plans during this call.

- Granules India has a strong and diverse product portfolio with a total of 127 dossiers filed across various regions. - They have 85 ANDAs in the US (16 pending approval), 18 dossiers in Europe (10 pending approval), and 24 in other regions including Canada (8 pending approval). - In Q4 FY '25, they filed 3 US ANDAs and 6 European dossiers, including a first-to-file product from the GPI facility. - The oncology pipeline includes around 10 products under development with filings already initiated in US and Europe. - The ADHD portfolio has about 10 products in the pipeline, including day 1 launches, day 181 opportunities, and some first-to-file. - The company expects the oncology portfolio to start yielding revenue from FY '28 onwards. - The focus remains on vertical integration and in-house API manufacturing to support these filings and commercial launches.